drugset

drugset / Trial / NCT00750555

Maintenance of Tarceva (Erlotinib) in Patients With Locally Advanced Head and Neck Cancer

NCT00750555 ↗

Phase 2 Terminated 4 enrolled Geisinger Clinic Genentech, Inc. · collab

NaSingle-groupOpen-labelTreatment

Summary

Phase II Study of Maintenance Tarceva (Erlotinib) in patients with locally advanced Head and Neck Cancer after treatment with curative intent

Timeline

Start: 2008-09
Primary completion: 2009-12
Completion: 2009-12

Outcome

Outcome not reported

Stopped (Enrollment): “PI Law left Geisinger-study terminated prematurely - 4 patients enrolled”

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Erlotinib	Small molecule	150 mg	Oral

Indications